Pharming Group reports financial results for the first quarter of 2023

FDA approval and commercial launch of Joenja® (leniolisib) in the U.S. Joenja® launch off to strong start with 23 U.S. patients on paid therapy Revenues...

Related Keywords

Japan ,London ,City Of ,United Kingdom ,Amsterdam ,Noord Holland ,Netherlands ,Australia ,Canada ,United States ,America ,Japanese ,Michael Levitan ,Heather Robertson ,Foster Mitchell Alex Shaw ,Pharming Group ,Vp Investor Relations Corporate Communications ,Linkedin ,Ministry Of Health ,Pharming Groupnv ,Exchange Commission ,European Medicines Agency ,Silicon Valley Bank ,Novartis ,Company Euronext ,Nasdaq ,European Commission Decision Reliance Procedure ,Lifespring Life Sciences Communication ,Investor Relations Corporate Communications ,Drug Administration ,Regulatory Agency ,Committee For Human Medicinal Products ,Executive Officer ,Sijmen De Vries ,New Drug Application ,Human Medicinal Products ,Marketing Authorisation Application ,Orphan Drug Designation ,Pediatric Investigational Plan ,Investigational New Drug ,Silicon Valley ,Marketing Authorisation ,General Meeting ,Shareholders May ,Investor Relations ,Corporate Communications ,Spring Life Sciences Communication ,North America ,Middle East ,Annual Report ,Consolidated Interim Financial Statements ,Consolidated Statement ,Comprehensive Income ,